Drug intelligence / Profile preview

PR115002

Development stage: Preclinical
Lead developer: Merna Therapeutics
Modality: Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

PR115002 is a novel sortilin-targeting peptide-drug conjugate (PDC) developed for the treatment of platinum-resistant ovarian cancer. As a peptide-drug conjugate, it consists of a targeting peptide that binds to sortilin, a cell surface receptor implicated in cancer cell survival and drug resistance, linked to a cytotoxic payload. By specifically targeting sortilin-expressing tumor cells, PR115002 aims to deliver its cytotoxic agent directly to malignant cells while sparing normal tissues. Preclinical studies have demonstrated efficacy in models of platinum-resistant ovarian cancer[1][2][3].

Targets

SORT1 (Sortilin)

Beyond the preview

Go deeper on PR115002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR115002.

Explore the full profile